Han Jennifer H, Goldstein Ellie J C, Wise Jacqueleen, Bilker Warren B, Tolomeo Pam, Lautenbach Ebbing
Division of Infectious Diseases, Department of Medicine.
Center for Clinical Epidemiology and Biostatistics, and.
Clin Infect Dis. 2017 Apr 1;64(7):839-844. doi: 10.1093/cid/ciw856.
The rapid emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a major public health threat, including in the long-term acute care hospital (LTACH) setting. Our objective in this study was to describe the epidemiologic characteristics of CRKP in a network of US LTACHs.
An observational study was performed among 64 LTACHs from January 2014 to March 2015. Clinical cultures were included, with the first CRKP isolate recovered from each patient per study quarter evaluated. LTACH and geographic area-based CRKP prevalence and clinical and microbiologic characteristics were described.
A total of 3846 K. pneumoniae cultures were identified, with an overall carbapenem resistance rate of 24.6%. There were significant differences in CRKP rates across geographic regions, with the highest in the West (42.2%). Of 946 CRKP isolates, 507 (53.6%) were from a respiratory source, 350 (37.0%) from a urinary source, and 9 (9.4%) from blood. Among 821 unique patients with CRKP colonization or infection, the median age was 73 years. There was a high prevalence of respiratory failure (39.8%) and the presence of a central venous catheter (50.9%) or tracheostomy (64.8%). Resistance rates of CRKP isolates were high for amikacin (59.2%) and fluoroquinolones (>97%). The resistance rate to colistin/polymyxin B was 16.1%.
Nearly 25% of K. pneumoniae clinical isolates in a US network of LTACHs were CRKP. Expansion of national surveillance efforts and improved communication among LTACHs and acute care hospitals will be critical for reducing the continued emergence of CRKP across the healthcare continuum.
耐碳青霉烯类肺炎克雷伯菌(CRKP)的迅速出现构成了重大的公共卫生威胁,在长期急性病医院(LTACH)环境中亦是如此。我们在本研究中的目的是描述美国LTACH网络中CRKP的流行病学特征。
于2014年1月至2015年3月在64家LTACH中进行了一项观察性研究。纳入临床培养物,对每个研究季度从每位患者分离出的首株CRKP进行评估。描述了基于LTACH和地理区域的CRKP患病率以及临床和微生物学特征。
共鉴定出3846株肺炎克雷伯菌培养物,总体碳青霉烯耐药率为24.6%。不同地理区域的CRKP发生率存在显著差异,西部最高(42.2%)。在946株CRKP分离株中,507株(53.6%)来自呼吸道,350株(37.0%)来自泌尿道,9株(9.4%)来自血液。在821例CRKP定植或感染的独特患者中,中位年龄为73岁。呼吸衰竭(39.8%)以及中心静脉导管(50.9%)或气管切开术(64.8%)的发生率很高。CRKP分离株对阿米卡星(59.2%)和氟喹诺酮类(>97%)的耐药率很高。对黏菌素/多黏菌素B的耐药率为16.1%。
在美国LTACH网络中,近25%的肺炎克雷伯菌临床分离株为CRKP。扩大国家监测力度以及改善LTACH与急症医院之间的沟通对于减少CRKP在整个医疗连续体中的持续出现至关重要。